Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Education | $1,200 | 1 | 56.2% |
| Unspecified | $538.75 | 6 | 25.3% |
| Travel and Lodging | $290.60 | 3 | 13.6% |
| Food and Beverage | $104.03 | 4 | 4.9% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kairos Surgical Inc | $1,217 | 2 | $0 (2021) |
| Vericel Corporation | $916.09 | 12 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $1,217 | 2 | Kairos Surgical Inc ($1,217) |
| 2018 | $916.09 | 12 | Vericel Corporation ($916.09) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/16/2021 | Kairos Surgical Inc | — | Education | In-kind items and services | $1,200.00 | General |
| 06/16/2021 | Kairos Surgical Inc | — | Food and Beverage | In-kind items and services | $17.29 | General |
| 07/01/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | Travel and Lodging | In-kind items and services | $71.94 | General |
| Category: Approved Product being studied for pediatric use | ||||||
| 07/01/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | Travel and Lodging | In-kind items and services | $26.00 | General |
| Category: Approved Product being studied for pediatric use | ||||||
| 06/09/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | Travel and Lodging | In-kind items and services | $192.66 | General |
| Category: Approved Product being studied for pediatric use | ||||||
| 06/09/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | Food and Beverage | In-kind items and services | $40.74 | General |
| Category: Approved Product being studied for pediatric use | ||||||
| 06/09/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: Approved Product being studied for pediatric use | ||||||
| 06/09/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Approved Product being studied for pediatric use | ||||||
| 03/10/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | — | In-kind items and services | $290.22 | Research |
| Study: A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK) • Category: Approved Product being studied for pediatric use | ||||||
| 03/10/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | — | In-kind items and services | $97.61 | Research |
| Study: A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK) • Category: Approved Product being studied for pediatric use | ||||||
| 03/10/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | — | In-kind items and services | $75.33 | Research |
| Study: A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK) • Category: Approved Product being studied for pediatric use | ||||||
| 03/10/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | — | In-kind items and services | $36.77 | Research |
| Study: A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK) • Category: Approved Product being studied for pediatric use | ||||||
| 03/10/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | — | In-kind items and services | $19.41 | Research |
| Study: A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK) • Category: Approved Product being studied for pediatric use | ||||||
| 03/10/2018 | Vericel Corporation | MACI _ PEAK Study (Drug) | — | In-kind items and services | $19.41 | Research |
| Study: A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK) • Category: Approved Product being studied for pediatric use | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Study of MACI in Patients Aged 10 to <17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee (PEAK) | Vericel Corporation | $538.75 | 6 |
About Dr. Roger Lyon, MD
Dr. Roger Lyon, MD is a Orthopaedic Surgery healthcare provider based in Burlington, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518918366.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Roger Lyon, MD has received a total of $2,133 in payments from pharmaceutical and medical device companies, with $1,217 received in 2021. These payments were reported across 14 transactions from 2 companies. The most common payment nature is "Education" ($1,200).
Practice Information
- Specialty Orthopaedic Surgery
- Location Burlington, WI
- Active Since 05/15/2006
- Last Updated 08/26/2024
- Taxonomy Code 207X00000X
- Entity Type Individual
- NPI Number 1518918366
Products in Payments
- MACI _ PEAK Study (Drug) $916.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Orthopaedic Surgery Doctors in Burlington
William Healy, Md, MD
Orthopaedic Surgery — Payments: $472,056
Brian Samuelsen, Md, MD
Orthopaedic Surgery — Payments: $56,304
Matthew Crawford, Md, MD
Orthopaedic Surgery — Payments: $40,645
Adam Shafritz, M.d, M.D
Orthopaedic Surgery — Payments: $27,072
Andrew Marcantonio, D.o, D.O
Orthopaedic Surgery — Payments: $24,205
Sunny Patel, M.d, M.D
Orthopaedic Surgery — Payments: $23,921